Day One Biopharmaceuticals Yönetim
Yönetim kriter kontrolleri 3/4
Day One Biopharmaceuticals' CEO is Jeremy Bender, appointed in Sep 2020, has a tenure of 4.17 years. total yearly compensation is $6.91M, comprised of 9.4% salary and 90.6% bonuses, including company stock and options. directly owns 1.69% of the company’s shares, worth $25.02M. The average tenure of the management team and the board of directors is 3.2 years and 3.7 years respectively.
Anahtar bilgiler
Jeremy Bender
İcra Kurulu Başkanı
US$6.9m
Toplam tazminat
| CEO maaş yüzdesi | 9.4% |
| CEO görev süresi | 4.2yrs |
| CEO sahipliği | 1.7% |
| Yönetim ortalama görev süresi | 3.2yrs |
| Yönetim Kurulu ortalama görev süresi | 3.7yrs |
Son yönetim güncellemeleri
Recent updates
We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Afford To Drive Business Growth
Jul 12
Day One Biopharmaceuticals: Still Uncertainty After FDA Approval
Jul 07Day One Pharmaceuticals: Ojemda Approval A Big Win, Current Valuation Fair
Apr 24We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely
Mar 18Navigating Day One Biopharmaceuticals' Financial Health And Clinical Prospects
Feb 01We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely
Dec 04We're Not Very Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Rate
Jun 19We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely
Mar 08Here's Why We're Not Too Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Situation
Nov 22Day One Biopharmaceuticals: Recent Strong Data, And Major Catalysts Ahead
Sep 04Day One Biopharmaceuticals GAAP EPS of -$0.60
Aug 04Day One Biopharmaceuticals, Inc.'s (NASDAQ:DAWN) Intrinsic Value Is Potentially 52% Above Its Share Price
Jun 18Day One Biopharmaceuticals: Early Pediatric Brain Cancer Data Makes Tentative Buy Case
Jun 15We're Not Very Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Rate
Apr 29An Intrinsic Calculation For Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Suggests It's 42% Undervalued
Jan 14Day One Biopharmaceuticals (NASDAQ:DAWN) Is In A Good Position To Deliver On Growth Plans
Dec 10Day One Biopharmaceuticals (NASDAQ:DAWN) Is In A Good Position To Deliver On Growth Plans
Aug 27Day One Biopharma draws bullish calls as quiet period ends
Jun 21CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$84m |
| Jun 30 2024 | n/a | n/a | -US$167m |
| Mar 31 2024 | n/a | n/a | -US$209m |
| Dec 31 2023 | US$7m | US$647k | -US$189m |
| Sep 30 2023 | n/a | n/a | -US$175m |
| Jun 30 2023 | n/a | n/a | -US$166m |
| Mar 31 2023 | n/a | n/a | -US$157m |
| Dec 31 2022 | US$5m | US$610k | -US$142m |
| Sep 30 2022 | n/a | n/a | -US$124m |
| Jun 30 2022 | n/a | n/a | -US$105m |
| Mar 31 2022 | n/a | n/a | -US$183m |
| Dec 31 2021 | US$20m | US$523k | -US$171m |
| Sep 30 2021 | n/a | n/a | -US$183m |
| Jun 30 2021 | n/a | n/a | -US$167m |
| Mar 31 2021 | n/a | n/a | -US$54m |
| Dec 31 2020 | US$3m | US$142k | -US$41m |
Tazminat ve Piyasa: Jeremy's total compensation ($USD6.91M) is about average for companies of similar size in the US market ($USD5.64M).
Tazminat ve Kazançlar: Jeremy's compensation has increased whilst the company is unprofitable.
CEO
Jeremy Bender (53 yo)
4.2yrs
Görev süresi
US$6,913,959
Tazminat
Dr. Jeremy Bender, Ph D., M.B.A. serves as Chief Executive Officer, President and Director of Day One Biopharmaceuticals, Inc. since September 2020. He serves as President, Chief Executive Officer and Dire...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO, President & Director | 4.2yrs | US$6.91m | 1.69% $ 25.0m | |
| Co-Founder and Head of R&D | 6.8yrs | US$2.49m | 2.08% $ 30.7m | |
| COO, CFO & Secretary | 3.8yrs | US$3.55m | 0.23% $ 3.4m | |
| General Counsel and Chief Compliance Officer | 2.1yrs | US$2.77m | 0.027% $ 394.5k | |
| Chief Technology Officer | no data | Veri yok | Veri yok | |
| Chief People Officer | 3.2yrs | Veri yok | Veri yok | |
| Chief Development Officer | no data | Veri yok | Veri yok | |
| Chief Commercial Officer | 1.8yrs | Veri yok | Veri yok | |
| Chief Medical Officer | less than a year | Veri yok | Veri yok |
3.2yrs
Ortalama Görev Süresi
53yo
Ortalama Yaş
Deneyimli Yönetim: DAWN's management team is considered experienced (3.2 years average tenure).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO, President & Director | 4.2yrs | US$6.91m | 1.69% $ 25.0m | |
| Independent Director | 4.2yrs | US$350.75k | 0.072% $ 1.1m | |
| Board Observer | no data | Veri yok | Veri yok | |
| Chairman of the Board & Lead Independent Director | 2.2yrs | US$383.38k | 0% $ 0 | |
| Board Observer | no data | Veri yok | Veri yok | |
| Independent Director | less than a year | Veri yok | 0% $ 0 | |
| Independent Director | 3.3yrs | US$342.88k | 0% $ 0 | |
| Independent Director | 4.9yrs | US$342.88k | 0% $ 0 | |
| Independent Director | 3.7yrs | US$351.75k | 0.040% $ 593.2k | |
| Independent Director | 3.8yrs | US$352.50k | 0.057% $ 839.6k | |
| Independent Director | less than a year | Veri yok | 0% $ 0 |
3.7yrs
Ortalama Görev Süresi
55yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: DAWN's board of directors are considered experienced (3.7 years average tenure).